Tevogen Bio (TVGN) Stock Price, News & Analysis

Company Overview

Tevogen Bio is a clinical-stage biotechnology company developing targeted T-cell therapies for viral diseases and cancer. The company’s approach is designed to use healthy-donor immune cells to create “off-the-shelf” treatments intended to selectively recognize and eliminate diseased cells while limiting damage to healthy tissue.

Tevogen’s lead investigational therapy, TVGN 489, is an allogeneic, virus-specific cytotoxic T-cell therapy being developed for conditions associated with Epstein-Barr virus, including multiple sclerosis. The company is also advancing its broader immunotherapy platform for potential applications in other viral infections and oncology, although these programs remain subject to clinical development and regulatory review.

Tevogen was founded by physician and biotechnology executive Ryan Saadi, who serves as the company’s chief executive officer and chairman. The company is based in the United States and is focused primarily on developing therapies for patients with significant unmet medical needs. Its securities began trading on the Nasdaq under the symbol TVGN following a business combination with Semper Paratus Acquisition Corporation.

Key Stats

• Today's Range: $6.78 to $7.15
• 50-Day Range: $6.31 to $7.85
• 52-Week Range: $3.64 to $39.00
• Volume: 2,739 shs
• Average Volume: 9,768 shs
• Market Capitalization: $44.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.00
• Consensus Rating: Reduce

Tevogen Bio Stock Analysis - MarketRank™

Tevogen Bio scored higher than 29% of companies evaluated by MarketBeat, and ranked 808th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Tevogen Bio has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tevogen Bio has a consensus price target of $100.00, representing about 1,374.9% upside from its current price of $6.78.

Amount of Analyst Coverage

Tevogen Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Tevogen Bio is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tevogen Bio is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.48% of the float of Tevogen Bio has been sold short.

Short Interest Ratio / Days to Cover

Tevogen Bio has a short interest ratio ("days to cover") of 10.58, which indicates bearish sentiment.

Change versus previous month

Short interest in Tevogen Bio has recently decreased by 4.69%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tevogen Bio does not currently pay a dividend.

Dividend Growth

Tevogen Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.45

News Sentiment

Tevogen Bio has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Tevogen Bio this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tevogen Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

65.60% of the stock of Tevogen Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Tevogen Bio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/11/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TVGN
• Previous Symbol: NASDAQ:TVGN
• CIK: 1860871
• Web: www.tevogen.com
• Phone: (646) 807-8832
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tevogen Bio: $100.00
• High Price Target: $100.00
• Low Price Target: $100.00
• Potential Upside/Downside: +1,374.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -468.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.33
• Quick Ratio: 0.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($211.84) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 6,510,000
• Free Float: 2,240,000
• Market Cap: $44.14 million
• Optionable: N/A
• Beta: 0.19